查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1358143

全球及中国骨质疏鬆药物市场（依药物类型及地区划分）

Global and China Osteoporosis Drugs Market, By Drug Type, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计2023年全球及中国骨质疏鬆药物市场规模将达146亿美元，预测期内（2023-2030年）年复合成长率为3.9%。

报告范围 报告详情
基准年 2022年 2023年市场规模 146亿美元
实绩资料 2018-2021 预测期 2023-2030
预测期年复合成长率 3.90% 2030年市场规模预测 191亿美元
2023年全球及中国骨质疏鬆药物市场占有率（按药物类型）
全球及中国骨质疏鬆药物市场-IMG1

骨质疏鬆症的特征是骨密度和品质下降，通常导致手腕、臀部和脊椎骨折。骨质疏鬆症是由要素引起的，包括遗传、钙、镁和维生素D摄取不足、厌食等饮食障碍失调、缺乏运动和过量饮酒。骨质疏鬆症是由于骨骼密度和骨量降低以及骨质和结构改变而发生的骨骼疾病。骨强度降低会增加骨折的风险。随着骨质疏鬆症患病的不断增加，核准和上市的新骨质疏鬆症药物数量不断增加，预计将在预测期内显着推动骨质疏鬆症药物市场的成长。

市场动态

研发活动的活性化有助于全球和中国骨质疏鬆症药物市场的成长。例如，根据Contemporary OB/GYN（致力于将科学转化为临床实践的月刊）2023年3月10日发表的一项研究显示，骨质疏鬆症的激素疗法（HT）停经后，可以增加腰椎骨骼密度（ BMD）并防止骨质流失。在这项大型横断面研究中，目前和过去使用的多种类型的荷尔蒙疗法，包括闭经女性使用的联合荷尔蒙避孕和停经后疗法，与停经后女性的骨骼保护相关，并且这些效果被证明即使在治疗停止后。该论文还得出结论，停止荷尔蒙治疗或改变给药会影响骨骼健康，包括骨折风险。

研究的主要特点

  • 本报告对全球和中国骨质疏鬆药物市场进行了详细分析，并呈现了以2022年为基准年的预测期（2023-2030）的市场规模和年复合成长率。
  • 它还揭示了各个细分市场的潜在收入机会，并为该市场说明了一系列有吸引力的投资提案。
  • 它还提供了有关市场促进因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
  • 它根据公司亮点、产品系列、主要亮点、财务实绩和策略等参数，介绍了全球和中国骨质疏鬆症治疗市场的主要企业。
  • 该报告的见解使行销人员和公司负责人能够就未来的产品发布、类型经营团队、市场扩张和行销策略做出资讯的决策。
  • 全球和中国骨质疏鬆症药物市场报告面向该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
  • 相关人员可以透过用于分析全球和中国骨质疏鬆药物市场的各种策略矩阵来促进决策。

目录

第1章调查目的和假设

  • 这项研究的目的
  • 假设
  • 简称

第2章市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第3章市场动态、法规及趋势分析

  • 市场动态
    • 促进因素
    • 抑制因素
    • 市场机会
  • 影响分析
  • 近期产品发布
  • 流行病学
  • 合併、收购和合作
  • 法规场景
  • 主要进展
  • PEST分析

第4章全球及中国骨质疏鬆药物市场，新型冠状病毒（COVID-19）影响分析

  • 经济影响
  • 新型冠状病毒（COVID-19）的流行病学
  • 对需求和供给的影响

第5章2018-2030年全球及中国骨质疏鬆药物市场（依药物类型）

  • 双磷酸盐
  • 阿崙膦酸钠
  • 利塞膦酸盐
  • 伊班膦酸钠
  • 唑来膦酸
  • 其他的
  • 降钙素
  • 荷尔蒙治疗
  • 选择性雌激素受体调节剂 (SERM)
  • 副甲状腺素相关蛋白 (PTHrP) 类似物
  • Rank 配体 (RANKL) 抑制剂

第6章2018-2030年全球及中国骨质疏鬆药物市场（依给药途径）

  • 口服
  • 可注射的
  • 其他的

第7章2018-2030年全球及中国骨质疏鬆药物市场（依配销通路）

  • 医院药房
  • 零售药房
  • 网路药房

第8章2018-2030年全球及中国骨质疏鬆药物市场分区域分析

  • 北美洲
  • 美国
  • 加拿大
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 其他亚太地区
  • 中国
  • 中东
  • GCC
  • 以色列
  • 其他中东地区
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第9章竞争形势

  • Merck KGaA
  • Lilly
  • Procter & Gamble
  • Enzo Biochem Inc.
  • Sanofi
  • Novartis AG
  • Wyeth Nutrition（A subsidiary of Pfizer Inc.）
  • Hoffmann-La Roche Ltd
  • GSP plc
  • UCB SA
  • Amgen Inc.
  • BeiGene, Inc.
  • Bone Biologics Corp
  • TEIJIN LIMITED
  • Eden Biologics（Formerly known as JHL Biotech Inc.）
  • Keros Therapeutics
  • Taro Pharmaceutical Industries Ltd.

第10章章

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI4018

The Global and China Osteoporosis Drugs Market is estimated to be valued at US$ 14.6 Bn in 2023 and is expected to exhibit a CAGR of 3.9% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 14.6 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 3.90% 2030 Value Projection: US$ 19.1 Bn
Global and China Osteoporosis Drugs Market Share (%), by Drug Type, 2023
Global and China Osteoporosis Drugs Market - IMG1

Osteoporosis is characterized by a decrease in the density and quality of bones, which frequently leads to broken wrist, hip, and spine bones. Various factors responsible for osteoporosis include, genetic factors; low intake of calcium, magnesium, and vitamin D; eating disorders such as anorexia, inactivity & immobility, and excessive alcohol intake. Osteoporosis is a bone disease that develops when bone mineral density and bone mass decreases, or when the quality or structure of bone changes. This can lead to a decrease in bone strength that can increase the risk of broken bones (fractures). Increasing approvals and launches of novel osteoporosis drugs along with increasing prevalence of osteoporasis is expected to significantly drive the osteoporosis treatment market growth over forecast period.

Market Dynamics

The increasing research & development activities are attributed to the growth of the global and China osteoporosis drugs market. For instance, according to a study shared by Contemporary OB/GYN- a monthly publication dedicated to translating science into clinical practice, on March 10, 2023, Hormone therapy (HT) for osteoporosis can increase lumbar spine bone mineral density (BMD) and prevent bone loss in post menopausal women. The large cross-sectional study showed that current and prior use of multiple types of hormone therapies, including combined hormone contraception used in premenopausal women and menopause hormone therapies, were linked with bone protection in postmenopausal women and that these effects persisted after discontinuation of treatment. The article also concluded that stopping HT and varying doses impact bone health, including fracture risk.

Key features of the study:

  • This report provides an in-depth analysis of the global and China osteoporosis drugs market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global and China osteoporosis drugs market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Merck KGaA, Lilly, Procter & Gamble, Enzo Biochem Inc., Sanofi, Novartis AG, Wyeth Nutrition (A subsidiary of Pfizer Inc.), F. Hoffmann-La Roche Ltd, GSK plc, UCB S.A., Amgen Inc., BeiGene, Inc., Bone Biologics Corp, TEIJIN LIMITED, Eden Biologics (Formerly known as JHL Biotech Inc.), Keros Therapeutics, and Taro Pharmaceutical Industries Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global and China osteoporosis drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global and China osteoporosis drugs market.

Detailed Segmentation:

  • Global and China Osteoporosis Drugs Market, By Drug Type:
    • Bisphosphonates
    • Alendronate
    • Risedronate
    • Ibandronate
    • Zoledronic Acid
    • Others
    • Calcitonin
    • Hormone Therapy
    • Selective Estrogen Receptor Modulators (SERMs)
    • Parathyroid Hormone-Related Protein (PTHrP) Analog
    • Rank Ligand (RANKL) Inhibitor
  • Global and China Osteoporosis Drugs Market, By Route of Administration:
    • Oral
    • Injectable
    • Others
  • Global and China Osteoporosis Drugs Market, By Distribution Channel:
    • Hospitall Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Global and China Osteoporosis Drugs Market, By Region:
    • North America
    • Europe
    • Asia-Pacific
    • Latin America
    • Middle East & Africa
  • Company Profiles
    • Merck KGaA
    • Lilly
    • Procter & Gamble
    • Enzo Biochem Inc.
    • Sanofi
    • Novartis AG
    • Wyeth Nutrition (A subsidiary of Pfizer Inc.)
    • F. Hoffmann-La Roche Ltd
    • GSP plc
    • UCB S.A.
    • Amgen Inc.
    • BeiGene, Inc.
    • Bone Biologics Corp
    • TEIJIN LIMITED
    • Eden Biologics (Formerly known as JHL Biotech Inc.)
    • Keros Therapeutics
    • Taro Pharmaceutical Industries Ltd.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Type
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Recent Product Launches
  • Epidemiology
  • Merger, Acquisition, and Collaborations
  • Regulatory Scenario
  • Key Developments
  • PEST Analysis

4. Global and China Osteoporosis Drugs Market- COVID-19 Impact Analysis

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global and China Osteoporosis Drugs Market, By Drug Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Bisphosphonates
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Alendronate
  • Risedronate
  • Ibandronate
  • Zoledronic Acid
  • Others
  • Calcitonin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Hormone Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Selective Estrogen Receptor Modulators (SERMs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Parathyroid Hormone-Related Protein (PTHrP) Analog
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Rank Ligand (RANKL) Inhibitor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

6. Global and China Osteoporosis Drugs Market, By Route of Administration, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Injectable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

7. Global and China Osteoporosis Drugs Market, By Distribution Channel, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

8. Global and China Osteoporosis Drugs Market, By Region, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Bn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • China
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2018- 2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Bn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Bn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Merck KGaA
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Lilly
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Procter & Gamble
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Enzo Biochem Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sanofi
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Wyeth Nutrition (A subsidiary of Pfizer Inc.)
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Hoffmann-La Roche Ltd
  • GSP plc
  • UCB S.A.
  • Amgen Inc.
  • BeiGene, Inc.
  • Bone Biologics Corp
  • TEIJIN LIMITED
  • Eden Biologics (Formerly known as JHL Biotech Inc.)
  • Keros Therapeutics
  • Taro Pharmaceutical Industries Ltd.

10. Section

  • Research Methodology
  • About Us